The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Defining The Function Of Apolipoprotein-D In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$457,231.00
Summary
Alzheimer's disease (AD) prevalence is rising and there is no curative treatment. Neurotoxic amyloid-beta peptide and concomitant lipid oxidation in the brain contribute to the cause of AD. We have identified a new pathway by which a protein called apoD may inhibit lipid oxidation in the AD brain. We will test the impact that changing apoD levels in neurons and in genetically modified mice has on neuron stress and AD-like characteristics. This may reveal new avenues to prevent or treat AD.
A Central Role For ER-Golgi Trafficking In Motor Neuron Disease
Funder
National Health and Medical Research Council
Funding Amount
$434,652.00
Summary
Amyotrophic lateral sclerosis (ALS) patients currently face a bleak future. In the common global form of disease, the average length of survival after diagnosis is 31 months. Current therapies have at best a modest effect on the course of the disease with little or no benefit in terms of overall patient survival. This study will address the basic underlying biochemical mechanisms of disease in both sporadic and genetic forms of ALS. This studies will lead to opportunities to develop new therapie ....Amyotrophic lateral sclerosis (ALS) patients currently face a bleak future. In the common global form of disease, the average length of survival after diagnosis is 31 months. Current therapies have at best a modest effect on the course of the disease with little or no benefit in terms of overall patient survival. This study will address the basic underlying biochemical mechanisms of disease in both sporadic and genetic forms of ALS. This studies will lead to opportunities to develop new therapies in the future.Read moreRead less
Neuronal communication relies on the process of exocytosis by which neurons release a neurotransmitter. Exocytosis is critical for the simplest muscle movement to complex tasks such as learning and memory, and is altered in several neurodegenerative pathologies. We will investigate how the protein Munc18 controls exocytosis. This research will be important for understanding how neurons communicate in health and disease and will be relevant to other processes such as insulin release in diabetes.
The Role Of PARK9 And Autophagy In Parkinson's Disease.
Funder
National Health and Medical Research Council
Funding Amount
$396,198.00
Summary
With an ageing population, the health burdens of neurodegenerative diseases such as Parkinson's disease (PD) are numerous. We have found a role for a PD suspectibility gene, PARK9, in autophagy- a neuroprotective degradative pathway, that may also be involved in keeping ÎSyn, a pivitol protein in PD, levels in check.
Glutamate is one of the major neurotransmitters in the brain. It plays a very important role in most brain functions such as the ability to learn and the development of memory, but the lack of control of glutamate concentrations in the brain also underlies many pathological changes that cause neurological disorders such Alzheimer's disease, disability following a stroke, motor neurone disease and Parkinson's disease. These diseases place an enormous social and economic burden on society and in o ....Glutamate is one of the major neurotransmitters in the brain. It plays a very important role in most brain functions such as the ability to learn and the development of memory, but the lack of control of glutamate concentrations in the brain also underlies many pathological changes that cause neurological disorders such Alzheimer's disease, disability following a stroke, motor neurone disease and Parkinson's disease. These diseases place an enormous social and economic burden on society and in order to better understand and treat these diseases it is important to understand some of the fundamental biochemical processes that underlie both normal and pathogical functions of the key neurotransmitter glutamate. This project will investigate how the concentrations of glutamate are tightly regulated to maintain normal brain function and also to avoid the potentially pathological consequences when these control mechanisms fail.Read moreRead less
Elucidating The Mechanisms By Which Bis(thiosemicarbazone)-copper Complexes Protect Neurons In Models Of Neurodegenerative Diseases
Funder
National Health and Medical Research Council
Funding Amount
$353,377.00
Summary
Dr Liddell is a neuroscientist investigating potential therapeutic agents for the treatment of diseases of affecting the brain such as Alzheimer’s disease and Parkinson’s disease. He is examining a class of metal-based compounds that are showing strong potential for disease treatment, and is investigating how these compounds work. The findings will be used to further develop and improve these therapeutic agents, and may help understand the underlying causes of these diseases.
Discovery Early Career Researcher Award - Grant ID: DE130101591
Funder
Australian Research Council
Funding Amount
$375,000.00
Summary
Novel postsynaptic functions of the microtubule-associated protein tau. The protein tau is present in abnormal deposits in brains of individuals with dementia. The main aim of this project is to unravel and understand in detail new roles of tau in neurons and thus shed new light into normal brain function. Understanding these new functions of tau will aid in identifying new ways to treat these debilitating diseases.
Improving neuronal cell function with cell permeable copper complexes. Metal-based drugs offer an exciting new approach to treatment of neurodegeneration. However, little is known about how cells metabolise these drugs and this information is critical for further drug development. This project will determine how metal-based drugs are metabolised by neuronal cells and how this may result in therapeutic benefit.
Cellular mechanisms that protect against copper-bound beta-amyloid. This project will investigate some of the brain’s own mechanisms for protecting itself against Alzheimer’s disease. Understanding these mechanisms will be important for developing future therapeutic strategies for treating Alzheimer’s disease.
Identification And Study Of Novel Conserved Molecule With An Axonal Protective Function
Funder
National Health and Medical Research Council
Funding Amount
$625,005.00
Summary
Axonal degeneration is a common feature of a number of neurodegenerative conditions, such as motor neuron, Parkinson’s, Alzheimer’s and Huntington’s diseases. However, the genetic causes that regulate this biological event are poorly understood. We have identified a novel, conserved axonal protective molecule. We will study how it functions, and if it can be exploited to protect diseased neurons.